DVA vs HCA
DaVita Inc. and HCA Healthcare, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | DVA | HCA |
|---|---|---|
| Revenue | $13.6B | $75.6B |
| Net income | $746.8M | $6.8B |
| Gross margin | · | · |
| Net margin | 7.9% | 10.3% |
| Return on equity | · | · |
| Diluted EPS | $9.84 | $28.33 |
| Dividend / share | · | $2.88 |
| Payout ratio | 0.0% | 10.0% |
| Free cash flow | $1.3B | $7.7B |
| Equity | $-651.1M | $-6.0B |
| Net debt / equity | · | · |
| Current ratio | 1.29× | 0.97× |
| Revenue CAGR 5y | 3.4% | 8.0% |
| Profit CAGR 5y | −0.7% | 12.6% |
HCA bills 5.5× the revenue of DVA, and keeps more of each dollar of revenue as profit (10.3% against 7.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | DVA | HCA |
|---|---|---|
| FY2025 | $13.6B | $75.6B |
| FY2024 | $12.8B | $70.6B |
| FY2023 | $12.1B | $65.0B |
| FY2022 | $11.6B | $60.2B |
| FY2021 | $11.6B | $58.8B |
| FY2020 | $11.6B | $51.5B |
| FY2019 | $11.4B | $51.3B |
| FY2018 | $11.4B | $46.7B |
| FY2017 | $10.9B | $43.6B |
| FY2016 | $10.7B | $41.5B |
Bottom line
| Fiscal year | DVA | HCA |
|---|---|---|
| FY2025 | $746.8M | $6.8B |
| FY2024 | $936.3M | $5.8B |
| FY2023 | $691.5M | $5.2B |
| FY2022 | $560.4M | $5.6B |
| FY2021 | $978.5M | $7.0B |
| FY2020 | $773.6M | $3.8B |
| FY2019 | $811.0M | $3.5B |
| FY2018 | $159.4M | $3.8B |
| FY2017 | $663.6M | $2.2B |
| FY2016 | $879.9M | $2.9B |
15 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$61,956,931,000 | HCA |
| FY2024 | −$57,787,450,000 | HCA |
| FY2023 | −$52,827,853,000 | HCA |
| FY2022 | −$48,623,106,000 | HCA |
| FY2021 | −$47,133,203,000 | HCA |
| FY2020 | −$39,982,396,000 | HCA |
| FY2019 | −$39,947,521,000 | HCA |
| FY2018 | −$35,272,149,000 | HCA |
| FY2017 | −$32,737,366,000 | HCA |
| FY2016 | −$30,782,533,000 | HCA |
| FY2014 | −$24,122,894,000 | HCA |
| FY2013 | −$22,417,950,000 | HCA |
| FY2012 | −$24,826,720,000 | HCA |
| FY2011 | −$22,950,194,000 | HCA |
| FY2010 | −$21,815,390,000 | HCA |
HCA has reported the higher revenue in every one of these 15 fiscal years. The gap has widened since the earliest year compared.
15 of 17 comparable fiscal years — a year missing data on either side is not counted.
15 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −2.4 pp | HCA |
| FY2024 | +0.3 pp | DVA |
| FY2023 | −1.5 pp | HCA |
| FY2022 | −4.6 pp | HCA |
| FY2021 | −2.7 pp | HCA |
| FY2020 | +0.1 pp | DVA |
| FY2019 | +0.9 pp | DVA |
| FY2018 | −6.5 pp | HCA |
| FY2017 | +1.3 pp | DVA |
| FY2016 | +1.4 pp | DVA |
| FY2014 | +0.3 pp | DVA |
| FY2013 | +0.6 pp | DVA |
| FY2012 | +1.8 pp | DVA |
| FY2011 | −1.1 pp | HCA |
| FY2010 | +2.2 pp | DVA |
The higher net margin has changed hands between DVA and HCA over this period.
15 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
HCA's net margin has been more volatile than DVA's over the 15 comparable fiscal years — 2.1 percentage points of standard deviation against 1.7.
15 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between DVA and HCA over these 15 fiscal years — DVA led in 9 and HCA in 6.
15 of 17 comparable fiscal years — a year missing data on either side is not counted.